<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02469987</url>
  </required_header>
  <id_info>
    <org_study_id>MYL-1402O-1002</org_study_id>
    <secondary_id>2014-005621-12</secondary_id>
    <nct_id>NCT02469987</nct_id>
  </id_info>
  <brief_title>Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers</brief_title>
  <official_title>A Single Center, Randomized, Double-blind, 3-arm Parallel Phase1 Study to Assess PK, Safety, and Tolerability of a Single 90 Min iv Infusion of 1 mg/kg MYL-1402O, EU Avastin®, and US Avastin® in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, single-dose, three-treatment, parallel group design PK comparability study of&#xD;
      MYL-1402O solution manufactured for Mylan compared to US and EU marketed Avastin® solution&#xD;
      (bevacizumab).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, single-dose, three-treatment, parallel group design PK comparability study of&#xD;
      MYL-1402O solution manufactured for Mylan compared to US and EU marketed Avastin® solution&#xD;
      (bevacizumab) in a total of 111 healthy, adult male volunteers (37 subjects per treatment&#xD;
      arm). After randomization, subjects will receive one of the following treatments: A single 1&#xD;
      mg/kg dose administered by i.v. infusion (25 mL over approximately 90 minutes) of MYL-1402O,&#xD;
      an equivalent i.v. infusion of US marketed Avastin® (1 mg/kg), or an equivalent i.v. infusion&#xD;
      of EU marketed Avastin® (1 mg/kg).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) for bevacizumab.</measure>
    <time_frame>pre-dose and 0.33, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, and 2352 hours after start of infusion.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of bevacizumab</measure>
    <time_frame>pre-dose and 0.33, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, and 2352 hours after start of infusion.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>up to 99 days.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety variable - immunogenicity</measure>
    <time_frame>Predose day 1, and days 15, 43, 71, and 99 post infusion</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>MYL-1402O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MYL-1402O (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US Marketed Avastin (R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU Marketed Avastin(R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MYL-1402O</intervention_name>
    <description>Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.</description>
    <arm_group_label>MYL-1402O</arm_group_label>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>US marketed Avastin(R)</intervention_name>
    <description>Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins</description>
    <arm_group_label>US Marketed Avastin (R)</arm_group_label>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EU marketed Avastin(R)</intervention_name>
    <description>Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.</description>
    <arm_group_label>EU Marketed Avastin(R)</arm_group_label>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males aged 18-55 yrs. (inclusive)&#xD;
&#xD;
          -  BMI: 19.0 to 30.0 kg/m2 (inclusive)&#xD;
&#xD;
          -  Weight: ≥ 60kg and ≤100kg&#xD;
&#xD;
          -  Subjects should be willing to use adequate contraception and not donate sperm from&#xD;
             admission to clinical research center until 6 months post dosing.&#xD;
&#xD;
          -  All intermittent medications should have be stopped at least 14days prior to admission&#xD;
             to the clinical research center.&#xD;
&#xD;
          -  All intermittent non topical medication must be stopped at least 30days prior to&#xD;
             admission to the clinical research center.&#xD;
&#xD;
          -  Ability and willingness to abstain from ETOH 48hrs prior to admission to the clinical&#xD;
             research center.&#xD;
&#xD;
          -  Medical history without significant findings per the PI&#xD;
&#xD;
          -  Resting supine systolic BP of ≤140mmHg and diastolic BP of ≤90mmHg&#xD;
&#xD;
          -  ECGs (via 12 lead) showing NCS findings per PI&#xD;
&#xD;
          -  All clinical laboratory tests of blood and urine, WNL and/or without clinically&#xD;
             significant findings&#xD;
&#xD;
          -  Willing/able to sign ICF&#xD;
&#xD;
          -  Normal bowel habits&#xD;
&#xD;
          -  Negative medical history regarding fecal blood positivity&#xD;
&#xD;
          -  Normal and/or NCS spot protein/creatinine (PCR) ratio.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in the current study&#xD;
&#xD;
          -  History of prior exposure to bevacizumab&#xD;
&#xD;
          -  Evidence of clinically significant findings&#xD;
&#xD;
          -  Cognitive and / or mentally impaired handicaps that would affect ability to make an&#xD;
             informed consent and/or remain compliant to the requirements of this trial.&#xD;
&#xD;
          -  History of relevant drug and/or food related allergies.&#xD;
&#xD;
          -  History of or known hypersensitivity to bevacizumab or other recombinant human or&#xD;
             humanized antibodies or inactive ingredients.&#xD;
&#xD;
          -  Tobacco product use w/I 1 yr. prior to drug administration.&#xD;
&#xD;
          -  History of ETOH and or drug abuse/addiction&#xD;
&#xD;
          -  Positive urine drug and ETOH screen for opiates, methadone, cocaine, amphetamines&#xD;
             including XTC, cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants&#xD;
             and ETOH.&#xD;
&#xD;
          -  Average intake of more than 24 units of ETOH / wk. (1 unit of ETOH equals ~250mL of&#xD;
             beer, 100mL of wine or 35mL of spirits).&#xD;
&#xD;
          -  Consumption of any foods containing poppy seeds w/I 48 hrs. prior to screening and&#xD;
             admission to the clinical research center&#xD;
&#xD;
          -  Positive screen for Hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV)&#xD;
             antibodies or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies.&#xD;
&#xD;
          -  Participation in a drug study w/I 60days or 5 half-lives of the previous drug.&#xD;
&#xD;
          -  Participation in more than 3 other drug studies in the 10months prior to drug&#xD;
             administration in the current protocol.&#xD;
&#xD;
          -  Donation or loss of more than 100mL of blood w/I 60days prior to drug administration.&#xD;
             Donation or loss of more than 1.5liters of blood w/I the 10months prior to drug&#xD;
             administration.&#xD;
&#xD;
          -  Strenuous exercise w/I 96 hrs. Prior to admission to the clinical research center.&#xD;
&#xD;
          -  Significant or acute illness w/I 5days prior to drug administration that may impact&#xD;
             safety assessments per the judgement of the PI.&#xD;
&#xD;
          -  Unsuitable veins for infusion and/or venepuncture&#xD;
&#xD;
          -  Surgery including surgery with suturing via a dental procedure or would dehiscence w/I&#xD;
             28days of dosing. Any planned surgery or dental procedures during the study and for at&#xD;
             least 30days after follow up.&#xD;
&#xD;
          -  Presence of a non-healing wound or fracture.&#xD;
&#xD;
          -  History of bleeding disorders&#xD;
&#xD;
          -  History of thromboembolic conditions&#xD;
&#xD;
          -  History of gastrointestinal perforations or any fistulae.&#xD;
&#xD;
          -  History of orthostatic hypotension, fainting spells, blackouts for any reasons.&#xD;
&#xD;
          -  History of hypertension&#xD;
&#xD;
          -  Medically significant dental disease or dental neglect with signs and or symptoms of&#xD;
             local or systemic infection that would likely require a dental procedure during the&#xD;
             course of study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew A. Hummel, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mylan Pharmaceuitcals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences - Early Development Services</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>August 7, 2015</last_update_submitted>
  <last_update_submitted_qc>August 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>MYL-1402O</keyword>
  <keyword>PK</keyword>
  <keyword>Avastin®</keyword>
  <keyword>biosimilarity</keyword>
  <keyword>male</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

